SG11202101889PA - Method for evaluating anti-infective drugs, vaccines, etc. using immortalized monocytic cells and induced cells - Google Patents

Method for evaluating anti-infective drugs, vaccines, etc. using immortalized monocytic cells and induced cells

Info

Publication number
SG11202101889PA
SG11202101889PA SG11202101889PA SG11202101889PA SG11202101889PA SG 11202101889P A SG11202101889P A SG 11202101889PA SG 11202101889P A SG11202101889P A SG 11202101889PA SG 11202101889P A SG11202101889P A SG 11202101889PA SG 11202101889P A SG11202101889P A SG 11202101889PA
Authority
SG
Singapore
Prior art keywords
cells
vaccines
infective drugs
evaluating anti
induced
Prior art date
Application number
SG11202101889PA
Inventor
Kazuo Miyazaki
Atsushi Yamanaka
Minoru Okada
Satoru SENJYU
Original Assignee
Mican Tech Inc
Univ Kumamoto
Univ Osaka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mican Tech Inc, Univ Kumamoto, Univ Osaka filed Critical Mican Tech Inc
Publication of SG11202101889PA publication Critical patent/SG11202101889PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24131—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG11202101889PA 2018-08-27 2019-08-26 Method for evaluating anti-infective drugs, vaccines, etc. using immortalized monocytic cells and induced cells SG11202101889PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018158512 2018-08-27
PCT/JP2019/033378 WO2020045368A1 (en) 2018-08-27 2019-08-26 Method for evaluating anti-infective drugs, vaccines, etc. using immortalized monocytic cells and induced cells

Publications (1)

Publication Number Publication Date
SG11202101889PA true SG11202101889PA (en) 2021-03-30

Family

ID=69644366

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101889PA SG11202101889PA (en) 2018-08-27 2019-08-26 Method for evaluating anti-infective drugs, vaccines, etc. using immortalized monocytic cells and induced cells

Country Status (6)

Country Link
US (1) US20210277361A1 (en)
EP (1) EP3845639A4 (en)
JP (1) JP7376013B2 (en)
CN (1) CN112601815A (en)
SG (1) SG11202101889PA (en)
WO (1) WO2020045368A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114729321A (en) * 2019-11-19 2022-07-08 迈凯恩技术有限公司 Method for evaluating safety of substance in vitro using human immortalized myeloid cells
WO2021230304A1 (en) * 2020-05-13 2021-11-18 Ａｇｃ株式会社 Method for producing human professional antigen-presenting cells
WO2022075384A1 (en) * 2020-10-07 2022-04-14 マイキャン・テクノロジーズ株式会社 Coronavirus-infective cells and method of preparing same
CN113345600B (en) * 2021-05-06 2024-02-27 中国食品药品检定研究院 Method for evaluating effectiveness of anti-infective drug injection and application thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1025209T3 (en) * 1997-08-28 2007-06-25 Cheil Jedang Corp An attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine
JP2001046061A (en) * 1999-08-04 2001-02-20 Handai Biseibutsubiyou Kenkyukai Weakened dengue virus and dengue fever vaccine using the same
MXPA03005373A (en) * 2000-12-13 2004-03-26 Inmunex Corp Method for generating immortal dendritic cell lines.
CN1408850A (en) * 2001-09-18 2003-04-09 王虹 Immortal technology for human blood dentritic cell
FR2848565B1 (en) * 2002-12-16 2007-04-06 Ets Francais Du Sang LINE OF GEN2.2 DENDRITIC CELLS
JPWO2008056734A1 (en) 2006-11-08 2010-02-25 国立大学法人 熊本大学 Method for producing dendritic cells from human embryonic stem cells
SG173194A1 (en) * 2009-02-17 2011-09-29 Glaxosmithkline Biolog Sa Inactivated dengue virus vaccine with aluminium-free adjuvant
JP5306943B2 (en) * 2009-08-24 2013-10-02 全国農業協同組合連合会 How to make an attenuated virus
WO2012043651A1 (en) 2010-09-30 2012-04-05 国立大学法人 熊本大学 Production method for myeloid blood cells
WO2015086739A1 (en) * 2013-12-12 2015-06-18 Intervet International B.V. Immortalized porcine alveolar macrophage
JP6903866B2 (en) 2016-01-27 2021-07-14 国立大学法人 熊本大学 Method for inducing proliferation of blood-derived monocytes

Also Published As

Publication number Publication date
CN112601815A (en) 2021-04-02
WO2020045368A1 (en) 2020-03-05
EP3845639A1 (en) 2021-07-07
EP3845639A4 (en) 2022-05-11
JPWO2020045368A1 (en) 2021-08-10
JP7376013B2 (en) 2023-11-08
US20210277361A1 (en) 2021-09-09

Similar Documents

Publication Publication Date Title
SG11202101889PA (en) Method for evaluating anti-infective drugs, vaccines, etc. using immortalized monocytic cells and induced cells
EP3146744B8 (en) Method, apparatus, and system for providing a security check
EP3351172A4 (en) Ear shape analysis method, ear shape analysis device, and method for generating ear shape model
DK3328467T3 (en) SENSOR, CARTRIDGE AND DRUG ADMINISTRATIVE DEVICE
EP3242627A4 (en) System, device, and method for improved intraoral scanning accuracy
HK1211372A1 (en) Method and device for checking attendance based on instant messaging application
EP3056144C0 (en) A system and method for generating and recording auditory steady-state responses with a speech-like stimulus
EP3618347A4 (en) Method and device for inputting verification code
PT3241645T (en) Device, modular system and method for inserting an elastic ring into an internal groove
IL283343B (en) Systems, apparatus, and assembling method thereof for administering a substance
EP3172722A4 (en) Method and system for fare collection and validation on a transportation network
EP3357476A4 (en) Drug inspection device and method, and program
EP3455759A4 (en) Neural network architectures for scoring and visualizing biological sequence variations using molecular phenotype, and systems and methods therefor
GB2538506B (en) A device, system and method for vibration sensitivity assessment
EP3669780C0 (en) Methods, devices and system for a compensated hearing test
MX2017015201A (en) Method and apparatus for constructing a concrete tower.
EP3362791C0 (en) System for certifying a detection of a gaseous substance exhaled by an individual, and method using the system
GB201819350D0 (en) Method for time drift measurement, seismic node and seismic node handling system
EP3208329A4 (en) Method for producing gamma-delta t cells, and pharmaceutical
HK1257659A1 (en) Toll collection system, position measurement method, and program
IL260062B (en) Method, device and system for handling, grading and vaccinating living birds
EP3600672A4 (en) System, fluidics cartridge, and methods for using actuated surface-attached posts for processing cells
GB2574644B (en) A location system, method, and calibration method
EP3592145C0 (en) System and method for vitrifying a biological substance
EP3459444A4 (en) Biological information measurement support device, biological information measurement device, biological information measurement support method, and biological information measurement support program